Neurogenic Bladder Symptom Score

1. Abstract

The Neurogenic Bladder Symptom Score (NBSS) is an internationally recognized, disease-specific patient-reported outcome measure (PROM) engineered to assess the subjective severity, clinical consequences, and psychosocial burden of neurogenic lower urinary tract dysfunction (NLUTD). Developed initially to address the clinical shortcomings of generic urological questionnaires—which regularly presuppose volitional voiding and ignore neuro-urological management techniques such as clean intermittent catheterization—the NBSS provides a nuanced, multidimensional appraisal of lower urinary tract symptoms across clinical cohorts, including individuals with spinal cord injury, multiple sclerosis, and spina bifida.

The Brazilian Portuguese cross-cultural adaptation and psychometric validation of the NBSS operationalizes this specialized instrument for Portuguese-speaking clinical and research environments. Comprising 24 items, the scale evaluates three core symptom domains: Incontinence (8 items), Storage and Voiding symptoms (7 items), and clinical Consequences (7 items), alongside two independent items that capture the primary bladder management strategy (Question 1) and global urinary-specific quality of life (Question 24). Total scores on the clinical symptom subscales range from 0 to 74, where elevated values represent heightened symptom severity, frequent adverse sequelae, and pronounced functional impairment.

Psychometric evaluation demonstrates strong internal consistency, evidenced by an overall Cronbach’s alpha of 0.81, and excellent temporal stability over a 7- to 14-day retest interval with an intraclass correlation coefficient (ICC) of 0.86. Construct validity is supported by significant convergent correlation with the Short Form of the Qualiveen questionnaire (Qualiveen-SF; r = 0.66, p < 0.001) and robust known-groups discriminant validity through analysis of variance (ANOVA) across subjective problem categories. The instrument exhibits semantic, idiomatic, and conceptual equivalence with the original English version, cementing its status as an essential clinical trial endpoint and longitudinal monitoring tool in neuro-rehabilitation.

2. Keywords

neurogenic bladder, lower urinary tract symptoms, patient-reported outcome measures, psychometrics, spinal cord injury, urinary incontinence, cross-cultural adaptation, quality of life, neuro-urology, construct validity, test-retest reliability, Qualiveen

3. Authors

The original conceptualization and development of the Neurogenic Bladder Symptom Score was spearheaded by Dr. Blayne Welk and colleagues at the Department of Surgery (Division of Urology) and the Department of Epidemiology and Biostatistics at Western University (London, Ontario, Canada). The Brazilian Portuguese adaptation and psychometric validation was conducted by an interdisciplinary consortium of urologists, physiatrists, and neuro-urology researchers from the University of São Paulo:

• Lisley Keller Liidtke Cintra, MD — Division of Urology, Hospital das Clínicas, Faculty of Medicine, University of São Paulo (FMUSP), São Paulo, Brazil.
• José de Bessa Jr., MD, PhD — Division of Urology, State University of Feira de Santana, Bahia, Brazil; and FMUSP, São Paulo, Brazil.
• Victor Ikky Kawahara, MD — Division of Urology, Hospital das Clínicas, FMUSP, São Paulo, Brazil.
• Thereza Phitoe Abe Ferreira, MD — Instituto de Medicina Física e Reabilitação (IMREA), Hospital das Clínicas, FMUSP, São Paulo, Brazil.
• Miguel Srougi, MD, PhD — Professor and Chair, Department of Urology, FMUSP, São Paulo, Brazil.
• Linamara Rizzo Battistella, MD, PhD — Department of Legal Medicine, Medical Ethics, Occupational Health and Physical Medicine and Rehabilitation, FMUSP, São Paulo, Brazil.
• Daniel Rúbio de Souza, MD — Division of Urology, Hospital das Clínicas, FMUSP, São Paulo, Brazil.
• Homero Bruschini, MD, PhD — Associate Professor, Division of Urology, FMUSP, São Paulo, Brazil.
• Cristiano Mendes Gomes, MD, PhD (Corresponding Author) — Associate Professor, Division of Urology, Hospital das Clínicas, FMUSP, São Paulo, Brazil. Email: [email protected].

4. Purpose

Neurogenic lower urinary tract dysfunction (NLUTD) constitutes one of the most debilitating, medically complex, and psychosocially disruptive secondary conditions secondary to acquired or congenital nervous system lesions. Conditions such as traumatic spinal cord injury (SCI), multiple sclerosis (MS), transverse myelitis, and myelomeningocele severely disrupt the neural coordination between the brainstem, spinal autonomic centers, and peripheral detrusor-sphincter mechanisms. Historically, clinical evaluation of this population leaned disproportionately on objective urodynamic parameters (e.g., detrusor leak point pressure, bladder compliance, maximum cystometric capacity) and clinician-observed sequelae.

Although urodynamic metrics remain the gold standard for preserving renal safety and stratifying upper urinary tract deterioration risks, they correlate poorly with day-to-day patient experiences, functional independence, and health-related quality of life (HRQoL). Conversely, traditional patient-reported questionnaires utilized in general urology—such as the International Prostate Symptom Score (IPSS) or the Overactive Bladder Questionnaire (OAB-q)—were calibrated around non-neurogenic, volitionally voiding populations. These instruments focus primarily on symptoms like hesitancy, strain, post-void dribbling, and nocturia, rendering them structurally inappropriate for patients relying on clean intermittent catheterization, indwelling suprapubic tubes, or reflexive condom collections. Furthermore, generic instruments omit life-threatening complications unique to neurogenic pathologies, such as autonomic dysreflexia, deep pelvic spasticity, and insidious, asymptomatic urinary tract infections (UTIs).

The NBSS was formulated to resolve this measurement disparity by establishing a psychometrically sound, standardized instrument specifically designed to quantify the multifaceted manifestations of neurogenic bladder. The purpose of the Brazilian Portuguese adaptation by Cintra and colleagues (2019) was to provide a linguistically, culturally, and psychometrically validated instrument for clinical care and academic research in Brazil. In clinical settings, the NBSS operationalizes symptom severity to guide pharmacological escalation (such as anticholinergics or beta-3 agonists), evaluate surgical interventions (e.g., intradetrusor onabotulinumtoxinA injections, augmentation cystoplasty, or urinary diversion), and detect subclinical decompensation before irreversible upper tract damage ensues. In research paradigms, the adapted NBSS affords a robust, cross-culturally comparable clinical endpoint, facilitating the integration of Latin American patient cohorts into international multi-center neuro-urological trials.

5. Psychological Construct

The core construct operationalized by the Neurogenic Bladder Symptom Score is neurogenic bladder symptom burden and functional interference. In psychometric and health psychology terms, this construct reflects the patient’s subjective appraisal of lower urinary tract impairment, secondary somatic complications, and the resulting disruption to daily behavioral, emotional, and social functioning. Rather than conceptualizing bladder pathology as a unidimensional physiological deficit, the NBSS models symptom burden as a multidimensional construct encompassing three interrelated clinical domains and an overarching health-related quality of life appraisal.

Incontinence Domain

The Incontinence domain (Items 2 to 9) captures the frequency, volume, and contextual phenomenology of involuntary urine loss. In neurogenic populations, urinary leakage often stems from neurogenic detrusor overactivity (NDO), intrinsic sphincter deficiency, or mechanical catheter bypass. The domain explores:

• Frequency of involuntary leakage episodes during daytime and nighttime hours.
• Circumstantial triggers, such as physical exertion, transfers, spastic episodes, or uninhibited detrusor contractions occurring without sensory awareness.
• Dependence on protective containment garments (pads, adult briefs) and the practical disruption associated with garment changes.
• The psychological toll of incontinence, including anxiety surrounding unexpected odor, visible wetness, and social embarrassment.

Storage and Voiding Domain

The Storage and Voiding domain (Items 10 to 16) examines the mechanical, sensory, and behavioral barriers encountered during the reservoir and evacuation phases of micturition. Because individuals with neurogenic dysfunction exhibit diverse bladder behaviors—ranging from complete detrusor areflexia to violent detrusor-sphincter dyssynergia (DSD)—this domain addresses:

• Urinary frequency and the subjective sensation of urgency, including neuropathic equivalents of urgency (e.g., abdominal fullness, increased lower extremity spasticity, sweating).
• Difficulty initiating voiding or catheterization, including urethral sphincter spasms that impede catheter insertion.
• Sensation of incomplete bladder emptying and post-evacuation fullness.
• Pain, burning, or neuropathic discomfort experienced in the lower abdomen, urethra, or suprapubic region during bladder filling or emptying.

Consequences Domain

The Consequences domain (Items 17 to 23) represents the most clinically differentiated aspect of the NBSS, tapping into neuro-urological sequelae not found in generic urological scales:

• Urinary Tract Infections: Frequency of symptomatic UTIs requiring systemic antibiotic therapy, alongside the functional debilitation caused by infection-induced spasticity.
• Autonomic Dysreflexia: Episodes of severe hypertension, diaphoresis, flushing, and pounding headache triggered by bladder distention or catheter blockage in individuals with spinal lesions at or above T6.
• Bowel Interference: The co-occurrence of neurogenic bowel dysfunction, specifically constipation, fecal impaction, and their mechanical exacerbation of urinary retention and catheter performance.
• Medical and Health Service Utilization: Unplanned emergency department visits, unscheduled clinical consultations, and hospitalizations secondary to acute urological emergencies (e.g., urosepsis, gross hematuria, false urethral passages).

Global Quality of Life and Bladder Management

The construct is bookended by two independent evaluative items. Question 1 identifies the primary bladder management modality (e.g., spontaneous voiding, clean intermittent self-catheterization, catheterization by a caregiver, indwelling urethral catheter, suprapubic cystostomy, or urinary diversion). Question 24 provides a global, summative index of urinary-specific quality of life using a Delighted-to-Terrible rating scale, operationalizing the respondent’s affective adaptation to life with neurogenic lower urinary tract dysfunction.

6. Theoretical Framework

The development and cross-cultural validation of the Neurogenic Bladder Symptom Score is underpinned by two complementary frameworks: the Wilson and Cleary Model of Health-Related Quality of Life and the World Health Organization’s International Classification of Functioning, Disability and Health (WHO-ICF).

The Wilson and Cleary Model of Patient Outcomes

The Wilson and Cleary conceptual model (1995) delineates health outcomes along a continuum of increasing complexity, progressing from biological and physiological variables to symptom status, functioning, general health perceptions, and overall quality of life:

• Biological/Physiological Factors: Neurological disruption (e.g., complete thoracic SCI, demyelinating MS plaques) resulting in detrusor-sphincter dyssynergia, elevated intravesical storage pressures, and loss of voluntary micturition control.
• Symptom Status: The conscious perception of physiological disruption, operationalized in the NBSS via the Incontinence, Storage/Voiding, and Consequences subscales.
• Functional Status: The capacity of the individual to execute self-care activities, transfer independently without leakage, and manage bladder emptying supplies.
• General Health Perceptions and Overall QoL: The patient’s subjective synthesis of these health tiers, captured by the final evaluative item on the NBSS.

By explicitly bridging the gap between physiological impairment (urodynamic metrics) and global quality of life, the NBSS captures the intermediate symptom and functional domains that dictate clinical intervention success from the patient’s vantage point.

The WHO International Classification of Functioning (ICF)

Under the ICF framework, disability is conceptualized not as a purely medical defect, but as a dynamic interaction between health conditions, body functions/structures, activity limitations, and participation restrictions:

• Body Functions and Structures (b610–b639): Impairments of urinary excretion, storage, and sensory functions.
• Activity (d530): Limitations in toileting activities, including self-catheterization, managing drainage systems, and skin hygiene.
• Participation (d700–d999): Restrictions in employment, community mobility, interpersonal relationships, and recreation due to fears of incontinence, equipment failure, or autonomic crises.

The NBSS systematically integrates these layers, offering clinicians a psychometric profile of how biological neurological impairment translates into daily activity limitations and personal disruption.

7. Validity

The psychometric validation of the Brazilian Portuguese Neurogenic Bladder Symptom Score executed by Cintra et al. (2019) followed international guidelines for the cross-cultural adaptation of self-report measures established by Beaton and Guillemin. Validation involved verifying content, convergent, and known-groups construct validity within a dedicated neurogenic population.

Content Validity

Content validity was evaluated by an expert multidisciplinary committee consisting of three academic urologists specializing in neuro-urology, a female pelvic medicine and reconstructive surgeon (urogynecologist), a physiatrist, and professional linguists. The committee analyzed forward-translations and back-translations, resolving discrepancies in idiomatic phrasing and confirming that every item mapped accurately to clinical realities experienced by Brazilian patients with spinal injuries and neurological diseases. Pre-testing in a pilot cohort of patients confirmed semantic clarity, item comprehensibility, and high face validity across various educational backgrounds.

Convergent Construct Validity

Convergent validity was examined by comparing the NBSS total score against the Brazilian Portuguese version of the Qualiveen-SF (Short Form Qualiveen), a validated disease-specific quality of life questionnaire for neurogenic urinary disorders. The bivariate correlation analysis revealed a statistically significant, moderate-to-strong positive correlation:

• Qualiveen-SF Total Score: Pearson correlation coefficient r = 0.66 (p < 0.001).

Because higher scores on both the NBSS and Qualiveen-SF signify greater symptom severity and worse quality of life, this strong positive association demonstrates that the NBSS accurately captures the underlying target construct of urinary-related health impairment.

Discriminant and Known-Groups Validity

Known-groups validity was tested to determine whether the NBSS could differentiate between clinical subgroups with distinct symptom severities. Participants rated their global bladder trouble on a single-item Likert scale categorized into ordinal tiers (e.g., mild, moderate, severe problem). A one-way analysis of variance (ANOVA) demonstrated a significant linear gradient across groups:

• Patients reporting mild overall bladder difficulties exhibited significantly lower NBSS total scores compared to those reporting moderate problems.
• Patients with severe global complaints had the highest NBSS total scores (p for trend < 0.001).

This progressive step-up in scores confirms that the instrument possesses excellent discriminant sensitivity to clinical severity, accurately reflecting the subjective magnitude of urological impairment.

8. Reliability

The reliability of the Brazilian Portuguese NBSS was evaluated through rigorous assessments of internal consistency and test-retest reproducibility across stable clinical participants.

Internal Consistency

Internal consistency was calculated using Cronbach’s alpha on the overall questionnaire items. The scale demonstrated robust internal consistency:

• Overall Scale Cronbach’s Alpha: α = 0.81

This coefficient exceeds the universally accepted psychometric threshold of 0.70 for exploratory research and meets the 0.80 benchmark recommended for clinical assessment tools. This value indicates high interrelatedness among items without excessive redundancy, confirming that the distinct symptom domains contribute harmoniously to a unified measurement of neurogenic bladder burden.

Test-Retest Reliability and Temporal Stability

To evaluate stability over time, the NBSS was re-administered to a subsample of clinically stable participants across a standardized interval of 7 to 14 days. During this wash-out period, no medical alterations, medication titrations, or surgical procedures were performed. Reproducibility was quantified using the two-way mixed-effects intraclass correlation coefficient (ICC) for absolute agreement:

• Test-Retest ICC: 0.86 (95% Confidence Interval: 0.77 – 0.92, p < 0.001)

An ICC value of 0.86 indicates excellent reproducibility and minimal random measurement error, verifying that the Brazilian Portuguese NBSS provides stable baseline data suitable for longitudinal clinical monitoring and pharmaceutical intervention trials.

9. Factor Analysis

In their cross-cultural adaptation study, Cintra et al. (2019) retained the structural architecture established during the original instrument development by Welk et al. (2013, 2014) rather than deriving a de novo factor structure via exploratory factor analysis (EFA). The conceptual and psychometric rationale for this decision was rooted in the sample size constraints typical of specialized neuro-trauma cohorts and the imperative to maintain direct structural equivalence with the international parent scale.

Original Structural Model (Welk et al.)

During the primary English validation across 197 neurological patients, Welk and colleagues employed item-to-subscale correlations, principal component techniques, and clinical expert panels to construct a three-factor solution:

1. Factor 1: Incontinence — Accounting for the primary proportion of symptom variance, this factor groups all items addressing leakage volume, frequency, pad usage, and unconscious loss.
2. Factor 2: Storage and Voiding Symptoms — Clustering items related to frequency, nocturia, urgency, initiation hesitancy, and voiding pain.
3. Factor 3: Clinical Consequences — Uniting complications including recurrent UTIs, autonomic dysreflexia, bowel constipation overlap, and emergency medical encounters.

Cross-Cultural Structural Alignment

The Brazilian validation confirmed that the three-factor tripartite structure preserved strong conceptual fidelity in the target population. While formal confirmatory factor analysis (CFA) fit indices (e.g., RMSEA, CFI, TLI) were not computed due to the modest sample size (n = 68), the scale exhibited high domain coherence. The strong convergent validity with the Qualiveen-SF (r = 0.66) and the high Cronbach’s alpha (0.81) confirm that the established factor model functions effectively within Brazilian neurogenic cohorts.

10. Instrument / Measurement Tool

• Test Type: Patient-Reported Outcome Measure (PROM) / Clinical Health Assessment Questionnaire.
• Administration Format: Self-administered paper-and-pencil or digital questionnaire; interviewer-administered format permitted for individuals with severe tetraplegia, tremors, visual impairments, or low functional literacy.
• Target Population: Adults (18 years of age and older) diagnosed with neurogenic lower urinary tract dysfunction secondary to spinal cord injury, multiple sclerosis, spina bifida, stroke, or related central nervous system disorders.
• Completion Time: Approximately 8 to 12 minutes.
• Total Item Count: 24 items.
• Scale Structure:
  • Question 1: Evaluates the primary method of bladder management (nominal categorization: e.g., spontaneous voiding, clean intermittent self-catheterization, caregiver catheterization, indwelling transurethral catheter, suprapubic cystostomy, external condom device). Not scored numerically within the symptom total.
  • Incontinence Subscale: Items 2 through 9 (8 items; assesses leakage frequency, triggers, volume, and protection).
  • Storage and Voiding Subscale: Items 10 through 16 (7 items; assesses storage frequency, urgency, hesitancy, and dysuria).
  • Consequences Subscale: Items 17 through 23 (7 items; assesses UTIs, antibiotic courses, autonomic dysreflexia, bowel dysfunction, and hospital visits).
  • Question 24: Global quality of life evaluation rated on a Delighted-to-Terrible Likert scale. Scored independently as a subjective HRQoL anchor.
• Response Format: 24 items, multiple-choice and Likert-type response formats (variable response tiers ranging from 0–2 up to 0–5 points per item depending on symptom frequency, severity, or event incidence).
• Scoring Rules:
  • Total score is derived by summing the points across the 22 symptom-specific items (Items 2 through 23).
  • Total Score Range: 0 to 74 points.
  • Score Directionality: Higher scores reflect greater symptom severity, higher complication rates, and worse functional impairment.
  • Subscale scores may be computed independently to profile domain-specific deficits (e.g., isolated severe incontinence versus severe infectious consequences).
  • Normative reference values from Brazilian SCI cohorts establish a median total score of 22 points (interquartile range: 13.25 – 33.75).

11. Permissions & Fee and Test Year

• Year of Publication: The original English NBSS was published in 2013/2014 by Dr. Blayne Welk and colleagues. The Brazilian Portuguese cross-cultural adaptation was completed and published in 2019.
• Intellectual Property & Copyright: The Neurogenic Bladder Symptom Score is copyrighted by Dr. Blayne Welk. The Brazilian Portuguese translation was conducted under formal authorization and licensing from the original copyright holder.
• Academic & Clinical Accessibility: The scale is accessible for non-commercial academic research, clinical rehabilitation, and public hospital audits, subject to proper bibliographic citation. Commercial clinical trials or sponsored pharmaceutical studies must seek formal written licensing agreements and user permissions from the copyright holder and developer.
• Inquiries and Licensing: Requests regarding the original English version and translation authorizations may be directed to Dr. Blayne Welk (Western University, London, Ontario, Canada). Inquiries regarding the Brazilian Portuguese version can be directed to Dr. Cristiano Mendes Gomes (Division of Urology, FMUSP; Email: [email protected]).

12. References

Anthoine, E., Moret, L., Regnault, A., Sébille, V., & Hardouin, J. B. (2014). Sample size used to validate a scale: A review of publications on newly-developed patient reported outcomes measures. Health and Quality of Life Outcomes, 12, Article 176. https://doi.org/10.1186/s12955-014-0176-2

Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., & Cockett, A. T. (1992). The American Urological Association symptom index for benign prostatic hyperplasia. The Journal of Urology, 148(5), 1549–1557. https://doi.org/10.1016/S0022-5347(17)36966-5

Beaton, D. E., Bombardier, C., Guillemin, F., & Ferraz, M. B. (2000). Guidelines for the process of cross-cultural adaptation of self-report measures. Spine, 25(24), 3186–3191. https://doi.org/10.1097/00007632-200012150-00014

Bellucci, C. H., Castro, F. S., Gomes, C. M., Bessa, J., Jr., Battistella, L. R., & de Fraga, R. (2015). Contemporary trends in the epidemiology of traumatic spinal cord injury: Changes in age and etiology. Neuroepidemiology, 44(2), 85–90. https://doi.org/10.1159/000371519

Bonniaud, V., Bryant, D., Parratte, B., & Guyatt, G. (2006). Qualiveen: A urinary disorder-specific instrument for use in clinical trials in multiple sclerosis. Archives of Physical Medicine and Rehabilitation, 87(12), 1661–1663. https://doi.org/10.1016/j.apmr.2006.08.345

Calado, A. A., Araujo, E. M., Barroso, U., Jr., Netto, J. M., Filho, M. Z., Macedo, A., Jr., Bagli, D., & Farhat, W. (2010). Cross-cultural adaptation of the Dysfunctional Voiding Symptom Score (DVSS) questionnaire for Brazilian children. International Brazilian Journal of Urology, 36(4), 458–463. https://doi.org/10.1590/S1677-55382010000400009

Cintra, L. K. L., Bessa, J., Jr., Kawahara, V. I., Ferreira, T. P. A., Srougi, M., Battistella, L. R., Souza, D. R., Bruschini, H., & Gomes, C. M. (2019). Cross-cultural adaptation and validation of the Neurogenic Bladder Symptom Score for Brazilian Portuguese. International Brazilian Journal of Urology, 45(4), 805–814. https://doi.org/10.1590/s1677-5538.ibju.2018.0335

Clark, R., Welk, B., & Baverstock, R. (2016). Patient reported outcome measures in neurogenic bladder. Translational Andrology and Urology, 5(1), 22–31. https://doi.org/10.3978/j.issn.2223-4683.2015.12.07

Costa, P., Perrouin-Verbe, B., Colvez, A., Didier, J., Marquis, P., Marrel, A., Leriche, B., & Group, Q. S. (2001). Quality of life in spinal cord injury patients with urinary difficulties: Development and validation of Qualiveen. European Urology, 39(1), 107–113. https://doi.org/10.1159/000052421

D’Ancona, C. A., Tamanini, J. T., Castro, S., & Rodrigues Netto, N., Jr. (2009). Quality of life of neurogenic patients: Translation and validation of the Portuguese version of Qualiveen. International Urology and Nephrology, 41(1), 29–34. https://doi.org/10.1007/s11255-008-9402-3

Danielsen, A. K., Pommergaard, H. C., Burcharth, J., Angenete, E., & Rosenberg, J. (2015). Translation of questionnaires measuring health-related quality of life is not standardized: A literature-based research study. PLOS ONE, 10(5), Article e0127050. https://doi.org/10.1371/journal.pone.0127050

Fragalà, E., Privitera, S., Giardina, R., Di Rosa, A., Russo, G. I., Favilla, V., Castelli, T., & Cimino, S. (2015). Association between the Neurogenic Bladder Symptom Score and urodynamic examination in multiple sclerosis patients with lower urinary tract dysfunction. International Neurourology Journal, 19(4), 272–277. https://doi.org/10.5213/inj.2015.19.4.272

Guillemin, F., Bombardier, C., & Beaton, D. (1993). Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. Journal of Clinical Epidemiology, 46(12), 1417–1432. https://doi.org/10.1016/0895-4356(93)90142-N

Keszei, A. P., Novak, M., & Streiner, D. L. (2010). Introduction to health measurement scales. Journal of Psychosomatic Research, 68(4), 319–323. https://doi.org/10.1016/j.jpsychores.2010.01.006

McKenna, S. P. (2011). Measuring patient-reported outcomes: Moving beyond misplaced common sense to hard science. BMC Medicine, 9, Article 86. https://doi.org/10.1186/1741-7015-9-86

Mokkink, L. B., Terwee, C. B., Patrick, D. L., Alonso, J., Stratford, P. W., Knol, D. L., Bouter, L. M., & de Vet, H. C. (2010). The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. Journal of Clinical Epidemiology, 63(7), 737–745. https://doi.org/10.1016/j.jclinepi.2010.02.006

Narang, G. L., & Welk, B. (2017). Patient-reported outcome measures in urology. Current Opinion in Urology, 27(4), 366–373. https://doi.org/10.1097/MOU.0000000000000412

Tamanini, J. T., D’Ancona, C. A., Botega, N. J., & Rodrigues Netto, N., Jr. (2004). Validation of the “International Consultation on Incontinence Questionnaire — Short Form” (ICIQ-SF) for Portuguese. Revista de Saúde Pública, 38(3), 438–444. https://doi.org/10.1590/S0034-89102004000300015

Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A., Knol, D. L., Dekker, J., Bouter, L. M., & de Vet, H. C. (2007). Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology, 60(1), 34–42. https://doi.org/10.1016/j.jclinepi.2006.03.012

Welk, B., Morrow, S., Madill, A., & Baverstock, R. (2013). The conceptualization and development of a patient-reported neurogenic bladder symptom score. Research and Reports in Urology, 5, 129–137. https://doi.org/10.2147/RRU.S50560

Welk, B., Morrow, S., Madill, A., & Baverstock, R. (2014). The validity and reliability of the Neurogenic Bladder Symptom Score. The Journal of Urology, 192(2), 452–457. https://doi.org/10.1016/j.juro.2014.01.027

Welk, B., Lenherr, S., Elliott, S., Stoffel, J., Presson, A. P., Zhang, C., & Myers, J. (2017). A pilot study of the responsiveness of the Neurogenic Bladder Symptom Score (NBSS). Canadian Urological Association Journal, 11(11), 376–380. https://doi.org/10.5489/cuaj.4833

Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

13. Items of the Scale